Simon Barnett
@SimonDBarnett
Partner + Head of Research @_DimensionCap | Focused on the Intersection of Compute + Bio | Prev: Public Biotech Investor | Chemical Engineering @JohnsHopkins
In a new Perspective published today in @GENBiotechJrnl, John Chodera (@jchodera) and I give an optimistic view on the future of neural network potentials (NNPs) for enabling advanced small molecule discovery and design. liebertpub.com/doi/10.1089/ge… Summary Thread Below! 🧵
It’s so disheartening to read the same headline every year for five years. Less than half of patients with metastatic breast cancer receive germline genetic testing for BRCA1/2—disallowing them from potentially receiving PARP inhibitors and tailored screening of the family.
Despite clear guidelines, germline genetic testing remains underutilized in patients with metastatic breast cancer. In our new study published in JCO Precision Oncology, we evaluated >15,000 patients with metastatic breast cancer and found that fewer than half received germline…
Compute (++) + Energy (++) = Heat (++) We are not prepared for heat generation at the nexus of these two macro shifts.
The marginal cost of compute is going to zero. The marginal cost of energy is going to zero. Plan accordingly.
+1 example for /accel’ing so hard you unintentionally hit /decel territory x.com/davidjglassmd/…
Can you accel so hard that you actually roundtrip back to decel'ing? I obviously do not love this vanity preimplantation genetic testing (PGT) service (for a litany of reasons). But I can accept it will get into the marketplace regardless. My only real concern - I'm…
Agree, this is the new status quo. Adapt or die. There’s some extremely brilliant science happening in China, combined with incredible work ethic. A rising tide floats all boats. The right response is to make domestic policy changes, galvanize discovery & development, and dial…
Everyone posting this today like it’s the end of the world, but it’s the first bell of the biotech renaissance
The healthcare system if there were a ‘best-in-class’ effect for diagnostics
Indeed, if only there were a best in class effect in diagnostics!
Thanks for the chat, @aditharun_! Check out Adith's post about the current state of ctDNA testing in oncology. He gives a historical perspective, contrasting ctDNA adoption against the conditions that led to the rapid adoption of x-rays at the turn of the 20th century! We…
cell-free DNA technology will be standard practice in the future to guide treatment decisions and diagnose diseases. But, why has adoption been slow? To gain insight into this, we can look at the history of the medical imaging revolution and how it took shape. What were the…
Come on down, this bad boy ain’t gonna turn into a green paradise by itself
DIMENSION is growing our research team! join @SimonDBarnett & @Bauer_LeSavage as we build the premier investment firm at the interface of tech & life sciences on the planet (pictured here taking notes in Arrakis). Worm spotting skills optional .. DMs open
Under or Over? By 2050, radiography will be completely taken over by cell-free ‘omics for monitoring solid tumor progression.
Congratulations to the @MonteRosaTx team for having their work featured on the cover of @ScienceMagazine! We (@_DimensionCap) are tremendously excited about the future of molecular glue degraders (MGDs) and induced proximity writ large. Even in 2025, we've only scratched the…
Today, we published new discoveries in a @ScienceMagazine cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs and our QuEEN™ discovery engine: bit.ly/4eBn8Q
As AI/ML approaches cross over from the scaled manipulation of bits to the physical world of atoms, it makes all the sense to me that they start with small molecule therapeutics. The $/atom economics are the highest. Positioning 20 atoms could be worth >$1B/year.
One of the best parts of my role is having the privilege of being surrounded by passionate and brilliant scientists working on extremely difficult problems. The @chaidiscovery team falls into that category unequivocally. I was pretty blown away by this data as well as the…
We’re excited to introduce Chai-2, a major breakthrough in molecular design. Chai-2 enables zero-shot antibody discovery in a 24-well plate, exceeding previous SOTA by >100x. Thread👇
Chai Discovery (@joshim5 @chaidiscovery) just released Chai-2, a model for "zero-shot antibody design in a 24-well plate." The most existing result? Chai-2 successfully generated binders for 50% of the 52 targets they assayed (100x better than SOTA)! Some thoughts below:
We had an excellent time attending our first #ASCO conference this year - so much so that we decided to write up our key takeaways and open questions that we have been mulling over for the past couple weeks.